lobbying_filings_raw: 3664d5c8-e22e-4d54-9c2c-1df3527ee676

Raw lobbying disclosure filings from the Senate Office of Public Records (SOPR). Each row is a single filing — registrations, quarterly reports, amendments, and terminations. Includes registrant and client names, reported income/expenses, filing period, and the full raw JSON from the API.

This data as json

filing_uuid filing_type registrant_id registrant_name client_id client_name filing_year filing_period received_date amount_reported is_amendment is_no_activity is_termination raw_json registrant_state registrant_country registrant_house_id client_state client_ppb_state client_country client_ppb_country client_general_description client_government_entity affiliated_org_count client_entity_id client_government_unit_id client_match_method client_match_confidence
3664d5c8-e22e-4d54-9c2c-1df3527ee676 Q2 321112 OMNICARE, INC. 186752 OMNICARE INC 2015 second_quarter 2015-07-10T09:16:38.803000-04:00 20000.0 0 0 0 {"url": "https://lda.senate.gov/api/v1/filings/3664d5c8-e22e-4d54-9c2c-1df3527ee676/", "filing_uuid": "3664d5c8-e22e-4d54-9c2c-1df3527ee676", "filing_type": "Q2", "filing_type_display": "2nd Quarter - Report", "filing_year": 2015, "filing_period": "second_quarter", "filing_period_display": "2nd Quarter (Apr 1 - June 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/3664d5c8-e22e-4d54-9c2c-1df3527ee676/print/", "filing_document_content_type": "text/html", "income": null, "expenses": "20000.00", "expenses_method": "a", "expenses_method_display": "Method A - Reporting amounts using LDA definitions only", "posted_by_name": "Elizabeth Terry", "dt_posted": "2015-07-10T09:16:38.803000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "1301 K St., NW", "registrant_address_2": "Suite 1100 East Tower", "registrant_different_address": false, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20005", "registrant": {"id": 321112, "url": "https://lda.senate.gov/api/v1/registrants/321112/", "house_registrant_id": 39609, "name": "OMNICARE, INC.", "description": null, "address_1": "1301 K St., NW", "address_2": "Suite 1100 East Tower", "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20005", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "ELIZABETH TERRY", "contact_telephone": "+1 202-772-3526", "dt_updated": "2022-04-06T16:07:55.597396-04:00"}, "client": {"id": 186752, "url": "https://lda.senate.gov/api/v1/clients/186752/", "client_id": 12, "name": "OMNICARE INC", "general_description": null, "client_government_entity": false, "client_self_select": true, "state": "DC", "state_display": "District of Columbia", "country": "US", "country_display": "United States of America", "ppb_state": "DC", "ppb_state_display": "District of Columbia", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "1899-12-30"}, "lobbying_activities": [{"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "Medicare Part D reimbursement;\nMedicare Part D audit policy;\nMedicare anti-fraud, waste and abuse policy;\nMedicaid FFS drug reimbursement;\nMedicare innovative health care and delivery models;\nPost-acute care payment policy reform;\nMedicare Part D network access issues;\nSafe-harbor and anti-kickback policy", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 58925, "prefix": null, "prefix_display": null, "first_name": "ELIZABETH", "nickname": null, "middle_name": null, "last_name": "TERRY", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": []}, {"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "Drug Enforcement Administration rule on disposal of controlled substances in long term care facilities;\nReclassification of hydrocodone-containing prescription drugs from Schedule III to Schedule II drugs;\nControlled substances policy;\nBiosimilars policy;\nHazardous drug handling policy;\nFDA drug compounding policy", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 58925, "prefix": null, "prefix_display": null, "first_name": "ELIZABETH", "nickname": null, "middle_name": null, "last_name": "TERRY", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": []}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} DC US 39609 DC DC US US   0 0        

Links from other tables